CompletedNCT03485287
MDMA-Assisted Psychotherapy for PTSD in Canada: An Open-Label Study
About this title
Read the official source — NCT03485287Medication studyAges 18+Canada
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Vancouver and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 13, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 4
- Sponsor
- Resilient Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT03485287
- Official title
Show the full official title
An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder (Canada)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vancouver · Montreal
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Resilient Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Midomafetamine HCl.
Who was this study for?
Listed age limits: from 18 years.
